Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Hospira, Inc. (HSP - Analyst Report) has been facing manufacturing issues over the past few quarters. In Nov 2012, the U.S. Food and Drug Administration (FDA) issued a directive prohibiting Hospira from importing its Symbiq medication infusion pumps, manufactured in Costa Rica, to the U.S. The directive is a setback for the company. The facility at Costa Rica makes most of Hospira’s infusion devices and sets (Symbiq, Plum etc.).

The import ban was expanded by the FDA in Feb 2013. Following the fresh directive, Hospira is also prohibited from importing Plum, GemStar and LifeCare PCA infusion pumps, manufactured in Costa Rica, to the U.S. Hospira expects the expansion of the import ban to adversely impact its 2013 net sales by $50–$100 million. Moreover, manufacturing issues at the company’s other facilities, such as the Boulder active pharmaceutical ingredient plant, Rocky Mountain, Lake Forest and IKKT are further challenges for the company.

In another development, Hospira initiated a voluntary nationwide recall of a couple of its injectable drugs- a lot of Reglan (metoclopramide) and two lots of Zofran (ondansetron). Hospira initiated the move due to vial defects. The FDA stated that glass strand particulates due to a defect on the part of the glass supplier were the reason behind this voluntary move by Hospira.

Though Hospira has not received reports pertaining to any adverse events associated with these lots, we believe further slipups will impact the drugs’ supplies. This will create another challenge for the company to overcome.

Hospira carries a Zacks Rank #2 (Buy). Companies like Boston Scientific Corporation (BSX - Analyst Report), Athersys, Inc. (ATHX - Snapshot Report) and Alexion Pharmaceuticals, Inc. (ALXN - Analyst Report) too are Zacks #2 Ranked stocks.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GROUP DXYN 15.84 +7.90%
BOFL HOLDING BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%